TAC1 and cancer: Aprepitant inhibits the binding of substance P to the NK1 receptor in the vomiting center, and is effective for late-onset CINV that cannot be prevented by 5-HT3 receptor antagonists and manifests within 120 h after cancer chemotherapy [3, 4].